Curebase Stock
Curebase is a provider of decentralized clinical research software solutions and services to patients and medical providers.
Sign up today and learn more about Curebase Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Curebase Stock
Curebase builds a digital clinical trial assistant that would alter how medical providers discover, activate, and administer clinical trials for their patients. It aims to run clinical trials faster and cheaper than anyone else via software that reduces recruitment times, automates manual steps, and lets drug companies distribute their trials to clinics. The company was established in 2017 and is based in San Francisco, California.
Investors
Bold Capital Partners
Mojo Vision, AliveCor, Mighty Buildings, Kindred AI, Curebase
Liquid 2 Ventures
Whatnot, Cerebral, Newfront Insurance, Swiftly, Mux, Parsley Health, Curebase
Funding History
| August 2018 | $120K |
|---|---|
| October 2018 | $2.5M |
| May 2021 | $15.0M |
Management
Founder & CEO
Tom Lemberg
CTO
Matthew Rials
Investor
Jeff Richards
Vice President Of Business Development
Wayne Bowden
Chief Operating Officer
Storm Stillman
Press
endpts - Aug, 5 2023
Decentralized trials startup Curebase scraps clinical operations business unit, narrows in on software platformindianweb2 - Jan, 24 2023
Prodigi.ai, the AI-powered Digital Diagnostic Platform Acquires Coimbatore-based Data Analytics Platform CubeBaseprnewswire - Jan, 4 2023
Curebase Celebrates Year of Growth, Organizational Maturityprnewswire - Dec, 2 2022
Curebase Partners with Redenlab to Expand Data Capture Capabilities in Pharma Trialsyourstory - Nov, 18 2022
Healthtech startup CureBay raises Rs 50 Cr in Series A round led by Elevar EquityEquityZen Recognized As:
